WG
LCTX icon

Winton Group’s Lineage Cell Therapeutics LCTX Stock Holding History

Winton Group’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,061
Closed -$69K – 893
2025
Q2 		$69K Buy
+76,061
New +$45.1K ﹤0.01% 795
2021
Q4 		– Sell
-62,869
Closed -$158K – 1230
2021
Q3 		$158K Buy
62,869
+9,260
+17% +$23.8K 0.01% 1263
2021
Q2 		$153K Buy
53,609
+9,596
+22% +$24.8K 0.01% 1368
2021
Q1 		$103K Buy
44,013
+9,242
+27% +$22.2K 0.01% 1332
2020
Q4 		$61K Sell
34,771
-32,761
-49% -$45.8K ﹤0.01% 1282
2020
Q3 		$63K Sell
67,532
-40,748
-38% -$36K ﹤0.01% 1434
2020
Q2 		$94K Sell
108,280
-10,655
-9% -$9.38K ﹤0.01% 1405
2020
Q1 		$98K Sell
118,935
-40,416
-25% -$40.3K ﹤0.01% 1326
2019
Q4 		$142K Buy
+159,351
New +$133K ﹤0.01% 1473

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winton Group's LCTX Position: Q3 2025 in Review

Winton Group sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 76,061 shares — an estimated $69K sold.

Winton Group first reported a position in LCTX in Q4 2019 and held it in 9 quarters. The position peaked at $158K in Q3 2021. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

  • Winton Group reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Winton Group sold 76,061 Lineage Cell Therapeutics shares in Q3 2025, an estimated $69K.
  • Winton Group first reported a position in Lineage Cell Therapeutics in Q4 2019 and held it in 9 quarters.
  • Winton Group's Lineage Cell Therapeutics position peaked at $158K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Winton Group's 13F filing for Q3 2025, filed 13 Nov 2025.